

# Resource Summary Report

Generated by [dkNET](#) on Aug 8, 2026

## CD3-VioBlue, human

RRID:AB\_10831672

Type: Antibody

---

### Proper Citation

Miltenyi Biotec Cat# 130-094-363, RRID:AB\_10831672

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_10831672](http://antibodyregistry.org/AB_10831672)

**Proper Citation:** Miltenyi Biotec Cat# 130-094-363, RRID:AB\_10831672

**Target Antigen:** CD3

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Discontinued: 1-2018; Target Distribution NK cells, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-133. (RRID:AB\_2725961).

**Antibody Name:** CD3-VioBlue, human

**Description:** This monoclonal targets CD3

**Target Organism:** human

**Clone ID:** BW264/56

**Antibody ID:** AB\_10831672

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-094-363

**Record Creation Time:** 20250820T014404+0000

**Record Last Update:** 20250820T114259+0000

---

### Ratings and Alerts

No rating or validation information has been found for CD3-VioBlue, human.

**Warning:** Discontinued: 2021

Discontinued: 1-2018; Target Distribution NK cells, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-133. (RRID:AB\_2725961).

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Thomé J, et al. (2025) C-reactive protein induced T cell activation is an indirect monocyte-dependent mechanism involving the CD80/CD28 pathway. *Frontiers in immunology*, 16, 1622865.

Mantion CF, et al. (2025) Evaluation of dasatinib and ponatinib for the control of CD123 CAR-T cell functionalities. *Molecular therapy. Oncology*, 33(4), 201097.

Fredon M, et al. (2024) Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells. *Cancer immunology research*, 12(8), 1090.

Béziat V, et al. (2021) Humans with inherited T cell CD28 deficiency are susceptible to skin papillomaviruses but are otherwise healthy. *Cell*, 184(14), 3812.